Propofol, a potent intravenous general anesthetic, acts as a positive allosteric modulator of inhibitory -aminobutyric acid receptors (GABA A R), and this interaction is a major determinant of propofol's anesthetic potency (1) (2) (3) . In contrast, propofol inhibits excitatory nicotinic acetylcholine receptors (nAChR) (4, 5) , which are also members of the Cys-loop superfamily of pentameric ligand gated ion channels, as well as GLIC, a prokaryotic homolog that is a protongated cation channel (6) .
Identification of propofol binding sites in GABA A Rs and nAChRs is necessary to determine whether propofol binds to equivalent or distinct sites in Cys-loop receptors when it produces opposing effects as a positive or negative allosteric modulator.
Cys-loop ligand-gated ion channels each consist of five identical or homologous subunits that associate around a central axis forming the ion channel (7, 8) . Models of 3-dimensional structures of these receptors have been derived from a cryoelectron microscopy structure of the Torpedo (muscle-type,  2 β) nAChR (9) and from recently determined high resolution crystal structures of the homopentameric receptors GluCl, an invertebrate glutamate-gated chloride channel (10) , and GLIC (11, 12) . Each subunit contains an N-terminal extracellular domain, a transmembrane domain made up of a loose bundle of four transmembrane helices (M1-M4), and an intracellular domain formed by the primary structure between the M3 and M4 helices. The M2 helices from each of the five subunits form the ion channel, and the M1, M3, and M4 helices form an outer ring partly exposed to lipid.
While there has been no direct identification of propofol binding sites in a GABA A R or nAChR, within GLIC crystals, propofol binds within an intrasubunit pocket formed by the four transmembrane helices (6) . Within GABA A R, photoreactive derivatives of etomidate, another intravenous anesthetic, identified an intersubunit etomidate binding site in the transmembrane domain at the interface between β and  subunits, the same interface that contains the GABA binding site in the extracellular domain (13, 14) . Within the Torpedo nAChR, etomidate analogs have been shown to bind to three distinct sites in the transmembrane domain: the ion channel, the - subunit interface, and the  subunit helix bundle (15, 16) . Each of these sites are potential binding pockets for propofol, a potent inhibitor of the Torpedo nAChR expressed in oocytes (IC 50 = 7 µM (17)).
In this report we use AziPm (2-isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol), a recently developed photoreactive propofol analog (18), to identify propofol binding sites in the Torpedo nAChR.
AziPm acts as a tadpole anesthetic similar in potency to propofol, and it potentiates GABA A R responses at anesthetic concentrations (18). While AziPm is related structurally to propofol ( Fig. 1) , it incorporates a photoreactive 3-trifluoromethyl 3-phenyl diazirine group which can react with most amino acid side chains, including aliphatics (19). AziPm also is related in structure to TID (Fig. 1) , a potent Torpedo nAChR inhibitor (20) that has been shown by photoaffinity labeling to bind in a state dependent manner to sites in the ion channel (21) and in the  subunit helix bundle (22, 23 After photolabeling on a preparative scale, membranes were pelleted by centrifugation and then resuspended in sample buffer for electrophoresis. The ,  and  subunit bands were excised from the Coomassie Blue-stained gels and recovered by passive elution, concentrated to <400 l by centrifugal filtration (Vivaspin 15 Mr 5,000 concentrators, Vivascience inc., Edgewood, NY), and then acetoneprecipitated and resuspended in 100-200 l of digestion buffer (12 mM Tris, 0.5 mM EDTA, 0.1 % SDS, pH 8.6). The nAChR  subunit gel band was excised from the stained gel, soaked in overlay buffer (125 mM Tris, 5% sucrose (w/v), 0.1% SDS (w/v), 1 mM dithiothreitol, pH 6.8), and then placed in the wells of a 15% acrylamide mapping gel for in-gel digestion with 100 µg of S.aureus V8 protease to generate four subunit fragments (V8-20 (20kDa), V8-18 (18kDa), V8-10 (10kDa) and V8-4 (4kDa)) that were visualized by GelCode  Blue stain (Pierce) (25). After electrophoresis, the fragments were eluted from the excised gel bands and resuspended in digestion buffer. -10) . The trypsin and EndoLys-C digests of β and δ subunits, respectively, were fractionated on small pore (16.5% T, 6%C) Tricine SDS-PAGE gels (26), and fragments beginning at the Ntermini of βM2, δM1, and δM2 were isolated by reversed phase HPLC (rpHPLC) fractionation of materials of ~10 kDa and 10-14 kDa eluted from the β and δ subunit digests, respectively (21,22). Fragments beginning at the N-termini of αM2 and αM4 were isolated by direct rpHPLC fractionation of the EndoLys-C and trypsin digests of αV8-20 and αV8-10 (27). To characterize [ 3 H]AziPm incorporation in subunit M2-M3 loops and M3 helices, aliquots of ,  and  subunits (~150 μg) were digested with V8 protease (100 μg) for 3 days. The digests were fractionated by rpHPLC and material recovered from the hydrophobic fractions was sequenced as described below (28).
rpHPLC and sequence analysis. nAChR subunit proteolytic fragments were fractionated on an Agilent 1100 binary reversed-phase HPLC system using a C4-Aquapore 7-m (100 x 2.1 mm) column with an upstream C2 guard column, at 40 o C. Peptide elution was monitored by absorbance at 215 nm. Aqueous trifluoroacetic acid (0.08%) was used as solvent A and acetonitrile (60%), 2-propanol (40%) and trifluoroacetic acid (0.05%) as solvent B. A nonlinear elution gradient increasing from 25% to 100% solvent B in 80 min was used at a flow rate of 200 l/min, with fractions of 0.5 ml collected.
N-terminal sequencing was performed on an Applied Biosystems Procise 492 protein sequencer, with 1/6 of the material from each cycle used to quantify the amount of PTH amino acid derivative obtained and 5/6 collected to measure the 3 H released. Pooled HPLC fractions containing 3 H labeled peptides were drop-loaded at 45 o C onto Applied Biosystems Micro TFA glass fiber filters, except for fractions containing M4 or M1 which, due to their low sequencing efficiency when loaded on glass fiber filters, were loaded onto PVDF filters using Prosorb  sample preparation cartidges. All filters were then treated with BiobrenePlus. To chemically isolate during sequence analysis the nAChR subunit fragments beginning at βThr-273, γThr-276, or δThr-281 within the M2-M3 loops (28), sequencing filters were treated with o-phthalaldehyde (OPA) prior to cycle 6 of Edman degradation, which contains a proline. OPA reacts with primary amines, but not with proline, a secondary amine. This treatment prevents further sequencing of other fragments on the filter that do not contain a proline at that cycle (24,29).
The efficiency of photolabeling of amino acid residues within a sequenced fragment was calculated from the increase in 3 H release at that cycle of Edman degradation (cpm x -cpm (x-1) ) and the increased mass of the PTH-amino acid released in cycle x. The masses of the released PTH-amino acids were quantified from their peak heights relative to the peak heights of PTH-amino acid standards and then fit by non-linear least square (SigmaPlot 11) to equation 2:
where f(x) is the mass of the peptide residue in cycle x (in pmol), I o is the initial amount of peptide (in pmol), and R is the average repetitive yield, a parameter dependent upon the amount of sample wash off and the efficiency of peptide bond cleavage at each cycle of Edman degradation. PTH-derivatives whose amounts cannot be accurately measured (Cys, His, Ser, Trp and Arg) were omitted from this fit.
The efficiency of photolabeling of amino acid residues (cpm/pmol) was then calculated using Equation 3:
Molecular modeling. A model of Torpedo californica nAChR structure based on the cryoelectron microscopy structure of the Torpedo maramorata nAChR (PDB code, 2BG9 (9)) was used to dock, using the Discovery studio (Accelrys, Inc) software package, AziPm molecules within (i) the ion channel, (ii) the  subunit helix bundle, and (iii) the - subunit interface. We docked AziPm using the CHARMmbased molecular dynamics simulated-annealing program CDOCKER.
A randomly oriented AziPm molecule was seeded at the center of binding site spheres positioned between M2-6 and M2-13 within the ion channel (r = 10 Å), within the pocket formed by M2-18, Phe-232 and Cys-236 in the  subunit helix bundle (r = 8 Å), or at the level of M2-10 in the - subunit interface (r = 8 Å). The CDOCKER program was set up to first seed fifty randomly distributed replicas of AziPm in the center of the spheres, and high temperature molecular dynamics was used to generate 50 random conformations for each replica. For each conformation, 400 energyminimized docking solutions were generated using simulated annealing and full potential minimization. Connolly surface representations defined by a 1.4 Å diameter probe of the ensemble of the 15 docking solutions with the lowest CDOCKER interaction energies are shown for each of the binding sites. Fig. 2A) .
RESULTS. Propofol and AziPm inhibition of
For nAChR-rich membranes in the presence of agonist at equilibrium, >99% of nAChRs are in the equilibrium desensitized state that binds ACh with highest afinity, while in the absence of agonist, ~85% of nAChRs are in the resting, closed channel state and ~15% in the desensitized state (30,31). Those conformations are interconvertible, and allosteric modulators such as PCP and proadifen increase the fraction of nAChRs in the desensitized state in the absence of agonist (stabilize the desensitized state) and enhance ACh equilibrium binding affinity (32, 33 = 134 ± 13 µM; Hill coefficient, n H = 2.5 ± 0.5) (Fig. 2A) .
We also examined the effects of propofol and AziPm on the equilibrium binding of nAChR channel blockers and found that propofol bound with higher affinity to the nAChR in the presence of agonist, while AziPm bound preferentially to the nAChR in absence of agonist. (Fig. 3A) and 3 H liquid scintillation counting (Fig. 3B) .
In the absence of agonist, [ 3 H]AziPm incorporated into each nAChR subunit, with the  subunit labeled most efficiently.
Tetracaine reduced  and β subunit photolabeling by 40 % and  subunit labeling by 60 %. Since tetracaine binds within the ion channel, this inhibition suggests that [ 3 H]AziPm photolabels residues within the ion channel. Propofol also inhibited labeling of the  subunit by 60%, but it increased  subunit incorporation by 20% (Fig. 3B) . For nAChRs in the absence of agonist, the 1,900 cpm of tetracaine-or propofol-inhibitable 3 H incorporation in the nAChR  subunit indicated photolabeling at 25 cpm/pmol  subunit (~0.5% of subunits).
In the presence compared to the absence of Carb, nAChR subunit photolabeling was reduced by ~20%. Propofol inhibited  subunit photolabeling by ~50%, while PCP reduced it by only 20%. As in the absence of agonist, propofol increased  subunit labeling ~20% in the presence of Carb.
To provide an initial localization of the photolabeled amino acids within the  subunit, we characterized the distribution of [ 3 H]AziPm incorporation within the large, non-overlapping fragments of the  subunit that can be generated by "in-gel" digestion with S. aureus V8-protease: fragments of 20 kDa (V8-20, beginning at Ser-173 and containing ACh binding site Segment C and the M1-M3 transmembrane helices), 18 kDa (V8-18, beginning at Thr-52 and containing ACh binding site Segments A and B), and 10 kDa (V8-10, beginning at Asn-339 and containing the cytoplasmic MA and transmembrane M4 helices) (9, 25) . For the nAChR photolabeled in the resting state, 59%, 3%, and 38% of 3 H were recovered in V8-20, V8-18, and V8-10, respectively (Fig. 3C) (Fig. 1) , binds within this pocket in the nAChR open and desensitized states, photolabeling amino acids in M1 (Phe-232 and Cys-236), M2 (Thr-274 (M2-18)), and M2-M3 loop (Ile-288) (22,23). To determine whether there was propofol-inhibitable [ 3 H]AziPm photolabeling of this site, we isolated and sequenced fragments beginning near the N-termini of M2 and M1 from nAChRs photolabeled in the presence of Carb ± 300M propofol. Sequence analysis of the M2 fragment (Fig. 5A ) revealed peaks ofArg-277, residues positioned within the  subunit helix bundle (9) . Propofol inhibited labeling of these residues by 80% and 75%, respectively. Nterminal sequencing through M1 (Fig. 5B) revealed peaks of 3 H release in cycles 27 and 31, consistent with photolabeling of Phe-232 and Cys-236 2 . Propofol inhibited labeling of these residues by 95% and 40%, respectively (Fig. 5B) .
When photolabeling was performed in the absence of Carb, no 3 H incorporation was detected in Phe-232, Cys-236, or Thr-274, indicating that if labeling occurred, it was at <5% the level seen in the presence of Carb (Fig. 5C) . We also characterized [ 3 H]AziPm photolabeling in the M2-M3 loop by isolating and sequencing a fragment beginning at Thr-281. In the presence of Carb, photolabeling of Ile-288, if it occurred, was at less than 3% the level of Phe-232 (data not shown).
[ 3 H]AziPm photoincorporation in M2. When nAChRs were photolabeled in the absence of agonist, [ 3 H]AziPm incorporation in the  subunit was inhibited by both propofol and tetracaine. However, propofol enhanced and tetracaine inhibited  subunit photolabeling (Fig.  3) .
Furthermore, the propofol-enhanced photolabeling in the  subunit was within V8-20, the 20 kDa fragment that contains the M1-M3 transmembrane helices. Sequence analysis of an  subunit fragment beginning at Met-243 (the Nterminus of M2), isolated from V8-20, revealed peaks of 3 H release in cycles 6 and 10 that established photolabeling of Ser-248 (M2-6) and Ser-252 (M2-10) (Fig. 6A) . Propofol reduced by 65% the labeling of M2-6, a position lining the lumen of the ion channel, while it increased by four-fold the photolabeling of M2-10, a position near the - and β- subunit interfaces (15, 16) . Sequence analysis of this Met-243 fragment isolated from nAChRs photolabeled in the presence of agonist (Fig. 6B) 3 H release in cycles 6 and 13 of Edman degradation established labeling of Ser-254 (βM2-6) and Val-261 (βM2-13) that was inhibited >90% by agonist (Fig. 7A ) and ~90% by propofol (Fig. 7B) . When the fragment beginning at Met-257 was sequenced, the peak of 3 H release in cycle 13 established labeling of Val-269 (M2-13) that agonist inhibited by >90% (Fig. 7C) and propofol inhibited by 85% (Fig. 7D) . Since positions M2-2, 6, 9, 13, 16, and 20 line the lumen of the ion channel (in all nAChR subunits and Cys-loop receptors (8) (15, 16) . In addition, the M3 helix of each subunit contains lipidexposed residues photolabeled by the hydrophobic probe, [ 125 I]TID (i.e., Phe-292, Leu-296, and Asn-300 (35)). To determine whether [ 3 H]AziPm photolabeled Met-295, Met-299, or other amino acids in M3, we isolated and sequenced a fragment beginning at Thr-276 from nAChRs photolabeled in the absence or presence of Carb (Fig. 8A) . There was no evidence of labeling of Met-295 or Met-299. However, there was a small peak of 3 H release in cycle 25, which indicated labeling of Asn-300 at similar efficiency in the absence and presence of agonist. When nAChR was photolabeled in the absence or presence of 300 µM propofol, the efficiency of photolabeling of Asn-300 differed by <10% (Table 1) . We also sequenced the corresponding fragments from the  and the β subunits that begin at Thr-281 and βLeu-275 and contain M3 and βM3. For the  (Fig. 8B ) and β subunit (not shown) fragments, there were peaks of 3 H release in cycle 25, which indicated incorporation at Asn-305 and βLeu-297, the positions in M3 and βM3 equivalent to Asn-300.
[ 
DISCUSSION
Propofol has been reported to be a potent inhibitor of 4β2 neuronal (IC 50 = 5 µM) and Torpedo nAChRs (IC 50 = 7 µM), but not mouse muscle nAChR (IC 50 = 45 µM) (5, 17) . In this study, we identify the Torpedo nAChR binding sites for [ 3 H]AziPm, a novel photoreactive propofol analog, and we use inhibition of [ 3 H]AziPm photolabeling to identify propofol binding sites. We summarize in Table 1 the photoincorporation efficiency (cpm/pmol) and pharmacological specificity for the labeled amino acids. Based upon the locations of the photolabeled residues in the structure of the nAChR (Fig. 9) , we find that [ 3 H]AziPm binds to three distinct sites within the nAChR transmembrane domain: (1) within the  subunit helix bundle in the desensitized state (photolabeling M2-18 and Phe-232/ Cys-236 in M1); (2) in the ion channel in the resting state (photolabeling M2-6, M2-6 and M2-13, and M2-13); and (3) at the - and/or β- transmembrane interface (photolabeling of M2-10).
Within the nAChR structural model, computational docking calculations predict that AziPm can bind to each of the three sites, and the predicted binding modes are shown in Fig. 9 3 H]TDBzl-etomidate photolabeling of M2-10 was enhanced in the presence of the desensitizing channel blockers PCP or proadifen. The photoetomidate binding site was located at the - interface based upon the photolabeling of Met-295/Met-299.
In the absence of photolabeling of similar amino acids in M3 or βM3, we do not know whether [ 3 H]AziPm binds at the - or β- interface (or both). In contrast to [ 3 H]AziPm, [ 125 I]TID did not photolabel M2-10, Met-295 or Met-299, although it photolabeled Asn-300 and other amino acids in the M3 helices that are exposed to lipid (35).
Propofol binding sites in Cys-loop receptors. Propofol acts as an inhibitor of muscle and neuronal nAChRs and of GLIC, and our results identify an intrasubunit propofol binding site in the Torpedo AChR transmembrane domain equivalent to the site identified in GLIC (6) . It remains to be determined whether propofol binds to an equivalent intrasubunit binding site in the GABA A receptor, where it acts as a positive allosteric modulator. For the Torpedo nAChR, the positive allosteric modulator TDBzl-etomidate does not bind within the pocket formed by the -subunit helix bundle. Instead, it binds to an intersubunit site at the interface between  and  subunit (15) . However, for the homopentameric 7 nAChR, mutational analyses provide evidence for an intrasubunit binding site for positive allosteric modulators within the helix bundle pocket (39,40).
General anesthetics of diverse chemical structure act as GABA A R positive allosteric modulators, and the results of early mutational analyses were interpreted in terms of structural models that predicted intrasubunit binding sites for alcohols and volatile anesthetics, as well as intravenous anesthetics including propofol and etomidate (41). However, improved GABA A R homology models indicate that many of the positions determining anesthetic sensitivity do not project within an intrasubunit pocket (42). In addition, photoreactive etomidate analogs identify an intersubunit etomidate binding site at the interface between β and  subunits that contain the GABA binding site in the extracellular domain (13, 14) , and in crystals of GluCl, a homopentameric invertebrate glutamate-gated chloride channel, the positive allosteric modulator ivermectin is bound at this intersubunit binding site (10 liquid scintillation counting. For each condition, the normalized subunit photolabeling, (( x - ns )/( 0 - ns ))100, was calculated from two gels with duplicate samples (mean ± SD), where  x is the  subunit 3 H cpm at propofol concentration x,  0 the 3 H cpm in the absence of propofol,  ns is the 3 H cpm incorporated in the presence of 100M tetracaine (Carb) or 300 µM propofol (+Carb). In the absence of Carb,  0 and  ns were 4295 ± 50 cpm and 1300 ± 50 cpm, respectively. In the presence of Carb,  0 and  ns were 3010 ± 15 cpm and 1170 ± 10 cpm (with 2060 ± 15 cpm incorporated in the presence of 100 µM PCP). The concentration dependence of propofol inhibition of b The data are presented as mean (±range) for the results from two independent photolabeling experiments for the conditions of Experiment 2, while the data of Experiments 1 and 3 are each from single experiments with one aliquot of each sample sequenced. The cpm/pmol are the values for positions at which the peak of 3 H release was >20% over the background release in the previous cycles. The upper limits of the photolabeling in the other cycles were determined from the random variation of the background release of 3 H in the adjacent sequencing cycles.
c For nAChRs in the desensitized state (+Carb), the substantial differences in photolabeling efficiency of amino acids in the  subunit helix bundle in Experiment 3 compared to Experiment 1 are likely to be related to the differences seen for [
125 I]TID photolabeling in the fast desensitized and equilibrium desensitized states (22,37). ND, not determined.
